Table 2 Use of azathioprine in the 37 patients who developed nodular regenerative hyperplasia.
| Variable | |
|---|---|
| Indication for azathioprine (n (%)) | |
| Chronic active, steroid dependent or steroid refractory | 28 (76) |
| disease | |
| Postoperative prophylaxis/recurrence | 2 (5) |
| Extensive Crohn's disease of the small intestine | 7 (19) |
| Azathioprine dose (median (range)) | |
| At data entry (mg/kg/d) | 2 (1.5 to 3.0) |
| Duration of azathioprine treatment (months) (median (range)) | |
| All patients | 37 (3 to 165) |
| Patients with portal hypertension (n = 31) | 34 (3 to 159) |
| Patients without portal hypertension (n = 6) | 37.5 (16 to 165) |
| Time between start of azathioprine and discovery of NRH (months) (median (range)) | 48 (6 to 187) |
NRH, nodular regenerative hyperplasia.